US oncology-focussed biotech firm Syndax Pharmaceuticals (Nasdaq: SNDX) has entered into an exclusive worldwide license agreement with Vitae Pharmaceuticals, a subsidiary of Ireland-incorporated Allergan (NYSE: AGN), for a portfolio of preclinical, orally-available small molecule inhibitors of the interaction of Menin with the mixed lineage leukemia (MLL) protein.
These compounds have potential application in the treatment of a genetically-defined subset of acute leukemias with chromosomal rearrangements in the MLL gene (MLL-r). Syndax expects to initiate clinical studies in 2019. Syndax itself is developing entinostat (also in combination with Merck KGaA and Pfizer’s avelumab, as well as with Merck & Co’s Keytruda) and SNDX-6352 in multiple cancer indications.
Financial terms of the deal
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze